Cited by 403Cancer-related Molecular PathwaysProtein Structure and DynamicsChemical Synthesis and Analysis

The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

Open access

Pazgier, Marzena, Liu, Min, Zou, Guozhang, Yuan, Weirong, Li, Changqing, Li, Chong, Li, Jing, Monbo, Juahdi, Zella, Davide, Tarasov, Sergey G., Lu, Wuyuan·2009·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0900947106PMC PMC2660734

Open this paper in CoChat — free account

Abstract

The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor suppressor protein p53—a cellular process initiated by MDM2 and/or MDMX binding to the N-terminal transactivation domain of p53. MDM2 and MDMX in many tumors confer p53 inactivation and tumor survival, and are important molecular targets for anticancer therapy. We screened a duodecimal peptide phage library against site-specifically biotinylated p53-binding domains of human MDM2 and MDMX chemically synthesized via native chemical ligation, and identified several peptide inhibitors of the p53-MDM2/MDMX interactions. The most potent inhibitor (TSFAEYWNLLSP), termed PMI, bound to MDM2 and MDMX at low nanomolar affinities—approximately 2 orders of magnitude stronger than the wild-type p53 peptide of the same length (ETFSDLWKLLPE). We solved the crystal structures of synthetic MDM2 and MDMX, both in complex with PMI, at 1.6 Å resolution. Comparative structural analysis identified an extensive, tightened intramolecular H-bonding network in bound PMI that contributed to its conformational stability, thus enhanced binding to the 2 oncogenic proteins. Importantly, the C-terminal residue Pro of PMI induced formation of a hydrophobic cleft in MDMX previously unseen in the structures of p53-bound MDM2 or MDMX. Our findings deciphered the structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX, shedding new light on structure-based rational design of different classes of p53 activators for potential therapeutic use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.0900947106

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Synthesis of Proteins by Native Chemical Ligation
Dawson, P. E., Muir, T. W., Clark‐Lewis, I., & Kent, S. B. H. (1994) · Science · doi:10.1126/science.7973629 · Cited by 4,190
How to measure and predict the molar absorption coefficient of a protein
Pace, C., Vajdos, F., Fee, L. R., Grimsley, G., & Gray, T. (1995) · Protein Science · doi:10.1002/pro.5560041120 · Cited by 3,924
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Growing evidence supports that in unstressed cells MDM2 primarily controls p53 stability through ubiquitylation to target the tumor suppressor protein for constitutive degradation by the proteasome (13, 14), whereas MDMX mainly functions as a significant p53 transcriptional antagonist independently of MDM2 (15, 16).”
Background
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231

Flagged first, then by citations

Show all 53 references

2 of the 53 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 403

Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering
Pérez, J. J., Pérez, R. A., & Pérez, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.681617 · Cited by 44
Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.010 · Cited by 46
Self-citation
Native and Engineered Cyclic Disulfide-Rich Peptides as Drug Leads
Tyler, T. J., Durek, T., & Craik, D. J. (2023) · Molecules · doi:10.3390/molecules28073189 · Cited by 42
Molecular Mimicry-Based Repositioning of Nutlin-3 to Anti-Apoptotic Bcl-2 Family Proteins
Ha, J., Won, E.-Y., Shin, J., Jang, M. K., Ryu, K., Bae, K., Park, S. G., Park, B. C., Yoon, H. S., & Chi, S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja109521f · Cited by 43
Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX
Spinnler, C., Hedström, E., Li, H., de Lange, J., Nikulenkov, F., Teunisse, A. F. A. S., Vries, M. V., Grinkevich, V. V., Jochemsen, A. G., & Selivanova, G. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.45 · Cited by 42
Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics
He, W., Yan, J., Li, Y., Yan, S., Wang, S., Hou, P., & Lu, W. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.041 · Cited by 42
Self-citation
A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties
He, W., Yan, J., Wang, L., Lei, B., Hou, P., Lu, W., & Ma, P. X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.026 · Cited by 41
Self-citation
Anatomy of Mdm2 and Mdm4 in evolution
Tan, B. X., Liew, H. P., Chua, J. S., Ghadessy, F. J., Tan, Y. S., Lane, D. P., & Coffill, C. R. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx002 · Cited by 40
Neue Modalitäten für schwierige Zielstrukturen in der Wirkstoffentwicklung
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie · doi:10.1002/ange.201611914 · Cited by 40
Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100
Dastidar, S. G., Lane, D. P., & Verma, C. S. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-s15-s6 · Cited by 40
Molecular Basis of Bcl-XL-p53 Interaction: Insights from Molecular Dynamics Simulations
Bharatham, N., Chi, S., & Yoon, H. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026014 · Cited by 40
Targeting Protein–Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches
Monti, A., Vitagliano, L., Caporale, A., Ruvo, M., & Doti, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097842 · Cited by 43
Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
Chee, S. M. Q., Wongsantichon, J., Quah, S. T., Robinson, R. C., Joseph, T. L., Verma, C. S., Lane, D. P., Brown, C. J., & Ghadessy, F. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104914 · Cited by 39
A tetrameric protein scaffold as a nano-carrier of antitumor peptides for cancer therapy
Ma, B., Niu, F., Qu, X., He, W., Feng, C., Wang, S., Ouyang, Z., Yan, J., Wen, Y., Xu, D., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.004 · Cited by 40
Self-citation
Targeted covalent inhibitors of MDM2 using electrophile-bearing stapled peptides
Charoenpattarapreeda, J., Tan, Y. S., Iegre, J., Walsh, S. J., Fowler, E., Eapen, R. S., Wu, Y., Sore, H. F., Verma, C. S., Itzhaki, L., et al. (2019) · Chemical Communications · doi:10.1039/c9cc04022f · Cited by 35
Review on Metal-Based Theranostic Nanoparticles for Cancer Therapy and Imaging
Fernandes, D. A. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231191493 · Cited by 46
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 41
Strategies for the Construction of Multicyclic Phage Display Libraries
Chen, F., Pinnette, N., & Gao, J. (2024) · ChemBioChem · doi:10.1002/cbic.202400072 · Cited by 37
Designer macrocyclic organo-peptide hybrids inhibit the interaction between p53 and HDM2/X by accommodating a functional α-helix
Smith, J. M., Frost, J. R., & Fasan, R. (2014) · Chemical Communications · doi:10.1039/c4cc01199f · Cited by 38
Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53–MDM2 interaction
Li, C., Zhan, C., Zhao, L., Chen, X., Lu, W., & Lu, W. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.039 · Cited by 37
Self-citation
Directed Evolution Using Stabilized Bacterial Peptide Display
Navaratna, T. A., Atangcho, L., Mahajan, M. K., Vivekanandan, S., Case, M., Min, A., Tresnak, D. T., & Thurber, G. M. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10716 · Cited by 35
Optimal Affinity Enhancement by a Conserved Flexible Linker Controls p53 Mimicry in MdmX
Borcherds, W. M., Becker, A., Chen, L., Chen, J., Chemes, L. B., & Daughdrill, G. W. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.04.017 · Cited by 35
Helix Stabilized, Thermostable, and Protease-Resistant Self-Assembled Peptide Nanostructures as Potential Inhibitors of Protein–Protein Interactions
Jeong, W., Lee, M. S., & Lim, Y. (2013) · Biomacromolecules · doi:10.1021/bm400532y · Cited by 36
Expanding the Chemical Diversity of Genetically Encoded Libraries
Iskandar, S. E., Haberman, V. A., & Bowers, A. A. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00179 · Cited by 35
Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive Leukemia
Ma, B., Feng, H., Feng, C., Liu, Y., Zhang, H., Wang, J., Wang, W., He, P., & Niu, F. (2022) · Advanced Science · doi:10.1002/advs.202104850 · Cited by 35
From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor
You, W., Zhou, Z., Li, Z., Yan, J., & Wang, Y. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101322 · Cited by 34
Monitoring Ligand-Induced Protein Ordering in Drug Discovery
Grace, C. R., Ban, D., Min, J., Mayasundari, A., Min, L., Finch, K. E., Griffiths, L. M., Bharatham, N., Bashford, D., Guy, R. K., et al. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.01.016 · Cited by 33
mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction
Shiheido, H., Takashima, H., Doi, N., & Yanagawa, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017898 · Cited by 33
Inhibitors of MDM2 and MDMX: A Structural Perspective
Riedinger, C., & McDonnell, J. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.75 · Cited by 32
Molecular Dynamic Simulation Insights into the Normal State and Restoration of p53 Function
Fu, T., Min, H., Xu, Y., Chen, J., & Li, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089709 · Cited by 32
Artificial Macrocycles as Potent p53–MDM2 Inhibitors
Estrada‐Ortiz, N., Neochoritis, C. G., Twarda‐Clapa, A., Musielak, B., Holak, T. A., & Dömling, A. S. S. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00219 · Cited by 32
Structure-guided disruption of the pseudopilus tip complex inhibits the Type II secretion in Pseudomonas aeruginosa
Zhang, Y., Faucher, F., Zhang, W., Wang, S., Neville, N., Poole, K., Zheng, J., & Jia, Z. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007343 · Cited by 32
Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2
Yadahalli, S., Neira, J. L., Johnson, C. M., Tan, Y. S., Rowling, P. J. E., Chattopadhyay, A., Verma, C. S., & Itzhaki, L. S. (2019) · Scientific Reports · doi:10.1038/s41598-018-36589-5 · Cited by 32
Constrained α-Helical Peptides as Inhibitors of Protein-Protein and Protein-DNA Interactions
Roy, S., Ghosh, P., Ahmed, I., Chakraborty, M., Naiya, G., & Ghosh, B. (2018) · Biomedicines · doi:10.3390/biomedicines6040118 · Cited by 33
Hitting Undruggable Targets: Viewing Stabilized Peptide Development through the Lens of Quantitative Systems Pharmacology
Atangcho, L., Navaratna, T. A., & Thurber, G. M. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.008 · Cited by 33
Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein–Protein Interactions
Shi, Y., Sang, P., Lu, J., Higbee, P. S., Chen, L., Yang, L., Odom, T., Daughdrill, G. W., Chen, J., & Cai, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01638 · Cited by 32
The Interplay of Disulfide Bonds, α-Helicity, and Hydrophobic Interactions Leads to Ultrahigh Proteolytic Stability of Peptides
Chen, Y., Yang, C., Li, T., Zhang, M., Liu, Y., Gauthier, M. A., Zhao, Y., & Wu, C. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00567 · Cited by 31
Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery
Thean, D., Ebo, J. S., Luxton, T., Lee, X. C., Yuen, T. Y., Ferrer, F. J., Johannes, C. W., Lane, D. P., & Brown, C. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-01712-5 · Cited by 31
Identifying Conformational-Selection and Induced-Fit Aspects in the Binding-Induced Folding of PMI from Markov State Modeling of Atomistic Simulations
Paul, F., Noé, F., & Weikl, T. R. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b12146 · Cited by 31
Chemical protein synthesis-assisted high-throughput screening strategies for d-peptides in drug discovery
Li, Y., Cao, X., Tian, C., & Zheng, J. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.04.015 · Cited by 29
A Review of Bioactive Peptides: Chemical Modification, Structural Characterization and Therapeutic Applications
Hou, H., Wang, J., Wang, J., Tang, W., Shaikh, A. S., Li, Y., Fu, J., Lu, L., Wang, F., Sun, F., et al. (2020) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2020.3001 · Cited by 29
Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides
Freitas, F. C., Ferreira, P. H. B., Favaro, D. C., & de Oliveira, R. J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01320 · Cited by 29
Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment
Chakraborty, K., Tripathi, A., Mishra, S., Mallick, A. M., & Roy, R. S. (2022) · Bioscience Reports · doi:10.1042/bsr20212051 · Cited by 30
High-Throughput Screening of Stapled Helical Peptides in Drug Discovery
Zhang, Y., Guo, J., Cheng, J., Zhang, Z., Kang, F., Wu, X., & Chu, Q. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01541 · Cited by 31
Directed Evolution of Highly Selective Proteases by Using a Novel FACS‐Based Screen that Capitalizes on the p53 Regulator MDM2
Yoo, T. H., Pogson, M., Iverson, B. L., & Georgiou, G. (2012) · ChemBioChem · doi:10.1002/cbic.201100718 · Cited by 29
Label-Free Real-Time Microarray Imaging of Cancer Protein–Protein Interactions and Their Inhibition by Small Molecules
Walgama, C. T., Mubarak, Z. H. A., Zhang, B., Akinwale, M., Pathiranage, A., Deng, J., Berlin, K. D., Benbrook, D. M., & Krishnan, S. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04234 · Cited by 27
Suprastapled Peptides: Hybridization-Enhanced Peptide Ligation and Enforced α-Helical Conformation for Affinity Selection of Combinatorial Libraries
Sabale, P. M., Imiołek, M., Raia, P., Barluenga, S., & Winssinger, N. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07013 · Cited by 28
Double Strain‐Promoted Macrocyclization for the Rapid Selection of Cell‐Active Stapled Peptides
Lau, Y. H., Wu, Y., Rossmann, M., Tan, B. X., de Andrade, P., Tan, Y. S., Verma, C. S., McKenzie, G. J., Venkitaraman, A. R., Hyvönen, M., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201508416 · Cited by 29
Competitive Binding between Dynamic p53 Transactivation Subdomains to Human MDM2 Protein
Shan, B., Li, D., Bruschweiler‐Li, L., & Brüschweiler, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.369793 · Cited by 28
Mirror image phage display – Generating stable therapeutically and diagnostically active peptides with biotechnological means
Sun, N., Funke, S. A., & Willbold, D. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.05.019 · Cited by 28
Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents
Mondal, C., Halder, A. K., Adhikari, N., Saha, A., Saha, K. D., Gayen, S., & Jha, T. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.011 · Cited by 27
Binary combinatorial scanning reveals potent poly-alanine-substituted inhibitors of protein-protein interactions
Ye, X., Lee, Y., Gates, Z. P., Ling, Y., Mortensen, J. C., Yang, F.-S., Lin, Y., & Pentelute, B. L. (2022) · Communications Chemistry · doi:10.1038/s42004-022-00737-w · Cited by 27
Assembly of Glycopeptides in Living Cells Resembling Viral Infection for Cargo Delivery
Tian, F., Guo, R., Wu, C., Liu, X., Zhang, Z., Wang, Y., Wang, H., Li, G., & Yu, Z. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202404703 · Cited by 26
Calculation of hot spots for protein–protein interaction in p53/PMI‐MDM2/MDMX complexes
Huang, D., Qi, Y., Song, J., & Zhang, J. Z. H. (2018) · Journal of Computational Chemistry · doi:10.1002/jcc.25592 · Cited by 26
Computational Studies of Difference in Binding Modes of Peptide and Non-Peptide Inhibitors to MDM2/MDMX Based on Molecular Dynamics Simulations
Chen, J., Zhang, D., Zhang, Y., & Li, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13022176 · Cited by 27
C-Terminal Substitution of MDM2 Interacting Peptides Modulates Binding Affinity by Distinctive Mechanisms
Brown, C. J., Dastidar, S. G., Quah, S. T., Lim, A., Chia, B. C. S., & Verma, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024122 · Cited by 26
Design of a novel MDM2 binding peptide based on the p53 family
Madhumalar, A., Jun, L. H., Brown, C. J., Lane, D. P., & Verma, C. S. (2009) · Cell Cycle · doi:10.4161/cc.8.17.9516 · Cited by 26
Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor
Qin, L., Yang, F., Zhou, C. K., Chen, Y., Zhang, H., & Su, Z. (2014) · Journal of the American Chemical Society · doi:10.1021/ja509223m · Cited by 26
Retracted
Surface Plasmon Resonance Sensing of Biorecognition Interactions within the Tumor Suppressor p53 Network
Moscetti, I., Cannistraro, S., & Bizzarri, A. R. (2017) · Sensors · doi:10.3390/s17112680 · Cited by 26
A systems wide mass spectrometric based linear motif screen to identify dominant in-vivo interacting proteins for the ubiquitin ligase MDM2
Nicholson, J., Scherl, A., Way, L., Blackburn, E. A., Walkinshaw, M. D., Ball, K. L., & Hupp, T. R. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.02.011 · Cited by 25
Novel Isoindolinone-Based Analogs of the Natural Cyclic Peptide Fenestin A: Synthesis and Antitumor Activity
Zhang, H., Wu, J., Wang, J., Xiao, S., Zhao, L., Yan, R., Wu, X., Wang, Z., Li, F., & Jin, Y. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00149 · Cited by 25
Affinity-based screening of MDM2/MDMX–p53 interaction inhibitors by chemical array: Identification of novel peptidic inhibitors
Noguchi, T., Oishi, S., Honda, K., Kondoh, Y., Saito, T., Kubo, T., Kaneda, M., Ohno, H., Osada, H., & Fujii, N. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.094 · Cited by 24
Development of a peptide-based inducer of protein degradation targeting NOTCH1
Ohoka, N., Misawa, T., Kurihara, M., Demizu, Y., & Naito, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.011 · Cited by 24
Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors
Cheng, X., Chen, R., Zhou, T., Zhang, B., Li, Z., Gao, M., Huang, Y., Liu, H., & Su, Z. (2022) · Nature Communications · doi:10.1038/s41467-022-28721-x · Cited by 23
Detecting protein–protein interactions based on kinase-mediated growth induction of mammalian cells
Mabe, S., Nagamune, T., & Kawahara, M. (2014) · Scientific Reports · doi:10.1038/srep06127 · Cited by 24
Regulation of MDM4
Markey, M. P. (2010) · Frontiers in bioscience · doi:10.2741/3780 · Cited by 26
Structural basis of how stress-induced MDMX phosphorylation activates p53
Chen, X., Gohain, N., Zhan, C., Lu, W.-Y., Pazgier, M., & Lu, W. (2015) · Oncogene · doi:10.1038/onc.2015.255 · Cited by 22
Self-citation
Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells
Philippe, G. J.-B., Mittermeier, A., Lawrence, N., Huang, Y., Condon, N. D., Loewer, A., Craik, D. J., & Henriques, S. T. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00988 · Cited by 23
Break CDK2/Cyclin E1 Interface Allosterically with Small Peptides
Chen, H., Zhao, Y., Li, H., Zhang, D., Huang, Y., Shen, Q., Duyne, R. V., Kashanchi, F., Zeng, C., & Liu, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109154 · Cited by 24
Peptide Activators of the p53 Tumor Suppressor
Zhan, C., & Lu, W. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222577 · Cited by 23
Self-citation
Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review
Teveroni, E., Lucà, R., Pellegrino, M., Ciolli, G., Pontecorvi, A., & Moretti, F. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1233179 · Cited by 23
N-Acylpolyamine inhibitors of HDM2 and HDMX binding to p53
Hayashi, R., Wang, D., Hara, T. J., Iera, J. A., Durell, S. R., & Appella, D. H. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.10.032 · Cited by 23
Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix–Loop–Helix Peptides with Cell Penetrating and Tumor Suppressor Properties
Philippe, G. J.-B., Gaspar, D., Sheng, C., Huang, Y., Benfield, A. H., Condon, N. D., Weidmann, J., Lawrence, N., Loewer, A., Castanho, M. A. R. B., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00593 · Cited by 24
Apoptosis in Leukemias: Regulation and Therapeutic Targeting
Samudio, I. J., Konopleva, M. Y., Carter, B., & Andreeff, M. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_12 · Cited by 22
Peptoid-based reprogrammable template for cell-permeable inhibitors of protein–protein interactions
Fukuda, Y., Yokomine, M., Kuroda, D., Tsumoto, K., Morimoto, J., & Sando, S. (2021) · Chemical Science · doi:10.1039/d1sc01560e · Cited by 21
Stabilization of α-helices by the self-assembly of macrocyclic peptides on the surface of gold nanoparticles for molecular recognition
Kim, B., Choi, S.-J., Han, S.-H., Choi, K., & Lim, Y. (2013) · Chemical Communications · doi:10.1039/c3cc44644a · Cited by 21
Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX
Lu, S., Jiang, Y., Zou, J., & Wu, T. (2011) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2011.07.003 · Cited by 21
Effect of Stapling on the Thermodynamics of mdm2–p53 Binding
Maity, A., Choudhury, A. R., & Chakrabarti, R. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00219 · Cited by 21
Markov models of the apo-MDM2 lid region reveal diffuse yet two-state binding dynamics and receptor poses for computational docking
Mukherjee, S., Pantelopulos, G. A., & Voelz, V. A. (2016) · Scientific Reports · doi:10.1038/srep31631 · Cited by 20
Efficient calculation of relative binding free energies by umbrella sampling perturbation
Zeller, F., & Zacharias, M. (2014) · Journal of Computational Chemistry · doi:10.1002/jcc.23744 · Cited by 20
Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations
Yadahalli, S., Li, J., Lane, D. P., Gosavi, S., & Verma, C. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-15930-4 · Cited by 19
Self-citation
Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors
Schneider, A. F. L., Kallen, J. A., Ottl, J., Reid, P., Ripoche, S., Ruetz, S., Stachyra, T., Hintermann, S., Dumelin, C. E., Hackenberger, C. P. R., et al. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00056j · Cited by 19
Controlled self-assembly of α-helix-decorated peptide nanostructures
Choi, S.-J., Jeong, W., Kim, T., & Lim, Y. (2011) · Soft Matter · doi:10.1039/c0sm01275k · Cited by 19
Novel Strategy Utilizing Extracellular Cysteine-Rich Domain of Membrane Receptor for Constructing d -Peptide Mediated Targeted Drug Delivery Systems: A Case Study on Fn14
Li, Z., Xie, J., Peng, S., Liu, S., Wang, Y., Lu, W., Shen, J., & Li, C. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00326 · Cited by 19
Self-citation
Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction
Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117358 · Cited by 19
Evaluating BindCraft for Generative Design of High-Affinity Peptides
Filius, M., Patsos, T., Minnee, H., Turco, G., Chong, H. E., Liu, J., Gnatzy, M. T., Rooth, R. S. M., Liu, A., Ta, R. D. T., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00774 · Cited by 25
A Supramolecular Nanomedicine Based on Bendamustine and MDM2‐Targeted D‐peptide Inhibitor for Breast Cancer Therapy
Zhou, Y., Chen, Y., Huang, X., Tan, Y., Hu, R., Li, C., & Niu, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100980 · Cited by 18
Self-citation
Conformational Biases of Linear Motifs
Cino, E. A., Choy, W., & Karttunen, M. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp407536p · Cited by 18
Simulating Molecular Mechanisms of the MDM2-Mediated Regulatory Interactions: A Conformational Selection Model of the MDM2 Lid Dynamics
Verkhivker, G. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040897 · Cited by 18
Stabilization of peptides against proteolysis through disulfide-bridged conjugation with synthetic aromatics
Chen, Y., Li, T., Li, J., Cheng, S., Wang, J., Verma, C. S., Zhao, Y., & Wu, C. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob02786e · Cited by 19
Self-citation
An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas
Touqan, N., Diggle, C. P., Verghese, E. T., Perry, S., Horgan, K. J., Merchant, W., Anwar, R., Markham, A. F., Carr, I., & Achuthan, R. (2013) · BMC Clinical Pathology · doi:10.1186/1472-6890-13-32 · Cited by 18
Merging the Isonitrile‐Tetrazine (4+1) Cycloaddition and the Ugi Four‐Component Reaction into a Single Multicomponent Process
Méndez, Y., Vasco, A. V., Ivey, G., Dias, A. L., Gierth, P. T., Sousa, B. B., Navo, C. D., Torres-Mozas, Á., Rodrigues, T., Jiménez‐Osés, G., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202311186 · Cited by 17
An update patent review of MDM2–p53 interaction inhibitors (2019–2023)
Twarda‐Clapa, A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2419836 · Cited by 17
Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2–p53 interaction
Niu, R., Zheng, Q., Zhang, J., & Zhang, H. (2013) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2013.10.005 · Cited by 17
Accelerating physical simulations of proteins by leveraging external knowledge
Pérez, A., Morrone, J. A., & Dill, K. A. (2017) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1309 · Cited by 17
Recognition-induced covalent capturing and labeling as a general strategy for protein detection
Li, H., Huang, Y., Yu, Y., Wang, Y., & Li, G. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.02.012 · Cited by 17
Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction
Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-67510-8 · Cited by 15
Delivery to, and Reactivation of, the p53 Pathway in Cancer Cells Using a Grafted Cyclotide Conjugated with a Cell-Penetrating Peptide
Philippe, G. J.-B., Huang, Y., Mittermeier, A., Brown, C. J., Kaas, Q., Ramlan, S. R., Wang, C. K. L., Lane, D. P., Loewer, A., Henriques, S. T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01682 · Cited by 17
Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)
Macchiarulo, A., Giacchè, N., Carotti, A., Moretti, F., & Pellicciari, R. (2011) · MedChemComm · doi:10.1039/c0md00238k · Cited by 16
Effect of Sequence and Stereochemistry Reversal on p53 Peptide Mimicry
Atzori, A., Baker, A. E., Chiu, M., Bryce, R. A., & Bonnet, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068723 · Cited by 16

Authors: Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., & Lu, W.
Affiliations: University of Maryland, Baltimore (US)
National Cancer Institute (US)
ORCID: Pazgier, Marzena
Liu, Min
Zou, Guozhang
Li, Changqing
Li, Chong
Li, Jing
Zella, Davide
Tarasov, Sergey G.
Lu, Wuyuan
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2009-03-24
Volume: 106
Issue: 12
Pages: 4665-4670
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0900947106
PMC: PMC2660734
OpenAlex: W2076060796
Cited by: 391
References: 53
Citations by year: 2026: 10 · 2025: 28 · 2024: 27 · 2023: 23 · 2022: 18 · 2021: 29 · 2020: 25 · 2019: 24 · 2018: 18 · 2017: 31 · 2016: 18 · 2015: 20 · 2014: 24 · 2013: 21 · 2012: 19
FWCI: 12.67
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (AI056264)
National Institute of Allergy and Infectious Diseases (AI 061482, AI 056264, R21AI056264, R01AI061482)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: p53, MDM2, MDMX, peptide inhibitors, transactivation domain, crystal structure, hydrogen bond network, hydrophobic cleft, p53 activators, anticancer drug design, phage display peptide library, native chemical ligation
MeSH terms: Amino Acid Sequence, Humans, Models, Molecular, Molecular Sequence Data, Nuclear Proteins, Oligopeptides, Peptides, Protein Binding, Proto-Oncogene Proteins, Structure-Activity Relationship, Tumor Suppressor Protein p53, Protein Structure, Secondary, Cell Cycle Proteins, Peptide Library, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks